LEXICON PHARMACEUTICALS, INC. Price-FCF Ratio
The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for the quarter ending 2024-12-31 was -1.49, a change of 0.81 year-over-year.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for the quarter ending 2024-09-30 was -2.72, a change of -0.74 year-over-year.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for the quarter ending 2024-06-30 was -2.11, a change of 1.74 year-over-year.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for the quarter ending 2024-03-31 was -3.18, a change of 1.47 year-over-year.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for fiscal 2024 was -1.49, a change of 0.81 from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for fiscal 2023 was -2.31, a change of 1.71 from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for fiscal 2022 was -4.02, a change of 2.63 from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. price-fcf ratio for fiscal 2021 was -6.65, a change of -3.84 from fiscal 2020.
- Available history
- 2011-09-30 to 2024-12-31
- Data captured
Historical Price-FCF Ratio
Annual Price-FCF Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |